Companies / ILA

ISLAND PHARMACEUTICALS LIMITED

ASX:ILAPharmaceuticals, Biotechnology & Life Sciences
295.9M shares on issueASX (delayed) · as of 28 July 2026$0.41price · delayed$118.4Mmarket cap · indicative
C
Dilution grade

Share count grew 133% in 24 months; 9 cash raises in 24 months; options/rights overhang 28% of shares

Cash runway9.4 quarters of funding
Share-count growth (24m)133.4%
Raise cadence (24m)9 cash raises
Options & rights overhang28.5% of shares
In-the-money supply16.9% of shares
Pending proposed issuesnone

ISLAND PHARMACEUTICALS LIMITED's ordinary share count grew 133.4% between June 2024 and April 2026, to 296M shares. The company raised capital nine times in that period for total disclosed proceeds of A$17.7M, most recently raising A$9.0M in January 2026. Options and rights on issue could convert into 84M new shares, equal to 28.5% of the current share count, of which 17% are in the money; the nearest expiry is December 2026. At the March 2026 quarter the company reported A$12.4M in available cash, about 9.4 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
28.5%
Max option dilution
16.9%
ITM option dilution
1
Raises · last 12 months
9.4 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 295.9M per ASX (delayed) (28 July 2026).
204.9M238.3M271.7MDec 24Sept 25July 26Cash raise · 30 Jan 2026Cash raise · 16 May 2025Cash raise · 19 Mar 2025Cash raise · 12 Mar 2025Cash raise · 5 Mar 2025Cash raise · 26 Feb 2025Cash raise · 19 Feb 2025Cash raise · 12 Feb 2025

Cash runway

9.4 qtrs
More than four quarters of funding at the recent spend rate.
$12.4M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
13 July 20263G · unquotedORDINARY FULLY PAID295.9MAppendix 3G
13 July 20263G · unquotedILA : ORDINARY FULLY PAID295.9MAppendix 3G
13 July 20263G · unquotedORDINARY FULLY PAID295.9MAppendix 3G
13 July 20263G · unquotedILA : ORDINARY FULLY PAID295.9MAppendix 3G
7 July 20263H · cancellationILA : ORDINARY FULLY PAID295.9MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

9 cash raises in the last 24 months · 1 in the last 12 months

$9.0M
Capital raise
30 Jan 2026
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

28.5%
Total overhang · of current shares
16.9%
In the money · at current price
84.2M
Potential new shares
Dec 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
3 Dec 2025Christopher NtoumenopoulosSell714k844k$25k3Y notice
3 Dec 2025Jason Alan CarrollBuy975k367k$68k3Y notice
12 Nov 2025Dr David FosterOther6.3M4.0M$2003Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026Investor Presentation - TechKnow Invest Roadshow
13 July 2026Notification regarding unquoted securities - ILA
13 July 2026Notification regarding unquoted securities - ILA
13 July 2026Notification regarding unquoted securities - ILA
13 July 2026Notification regarding unquoted securities - ILA
12 July 2026$PTexas Biomed SOW accelerates pivotal FDA pathway
8 July 2026$PInvestor Presentation - Ebola Clinical Program
7 July 2026Notification of cessation of securities - ILA
6 July 2026$PGalidesivir approved for treatment use in in Ebola epidemic
3 July 2026$PTrading Halt
3 July 2026$PPause in Trading
1 July 2026$PSingapore Patent Expands Island's ISLA 101 Viral Protection
16 June 2026$PFDA Grants Orphan Designation for Galidesivir in Marburg
15 June 2026$PInvestor Presentation - Asia Dengue Summit
11 June 2026Investor presentation (updated)
10 June 2026$PInvestor presentation
9 June 2026$PIsland Secures USAMRIID Support for Galidesivir Study
3 June 2026$PIsland Advances Galidesivir GMP Manufacturing for Biodefence
20 May 2026$PIsland Adds Biodefence Leader as Filovirus Risks Escalate
18 May 2026$PIsland Bolsters US Biodefence Readiness Ahead of Trials

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.